Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours
Author:
Funder
Exelixis, Inc
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference20 articles.
1. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth;Yakes;Mol Cancer Ther,2011
2. Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling;Nguyen;PLoS One,2013
3. Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions;Dai;Clin Cancer Res,2014
4. Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group;Gray;Clin Cancer Res,2006
5. Randomized discontinuation design: application to cytostatic antineoplastic agents;Rosner;J Clin Oncol,2002
Cited by 65 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Hallmarks of pancreatic cancer: spotlight on TAM receptors;eBioMedicine;2024-09
2. Small-molecule-based targeted therapy in liver cancer;Molecular Therapy;2024-08
3. A phase II study of cabozantinib and pembrolizumab in advanced gastric/gastroesophageal adenocarcinomas resistant or refractory to immune checkpoint inhibitors;The Oncologist;2024-06-01
4. Comparative efficacy and safety of cabozantinib for malignant tumors: a systematic review and meta-analysis;Expert Review of Anticancer Therapy;2024-04
5. Research Progression in the Mechanism of Bone Metastasis and Bone-Targeted Drugs in Prostate Cancer;annals of urologic oncology;2024-02-24
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3